Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Total Non-Current Liabilities data on file, last reported at $197.8 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 13.69% year-over-year to $197.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $197.8 million (down 13.69% YoY) and the FY2025 annual result came in at $215.8 million, down 12.86% from the prior year.
• Total Non-Current Liabilities rose to $197.8 million in Q1 2026, from $100.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $249.7 million in Q2 2024 to a low of $46.3 million in Q4 2022.
• A 5-year average of $137.9 million and a median of $100.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 409.83% — and 2025, when it plunged 59.22%.
• Tracing ENTA's Total Non-Current Liabilities over 5 years: stood at $46.3 million in 2022, then jumped by 409.83% to $236.0 million in 2023, then increased by 0.26% to $236.6 million in 2024, then tumbled by 57.69% to $100.1 million in 2025, then soared by 97.66% to $197.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $197.8 million (Q1 2026), $100.1 million (Q4 2025), and $215.8 million (Q3 2025), per Business Quant data.